Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that pre-operative statin use is neuroprotective at maximal
doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin
doses for two weeks (12-18 days) prior to CEA using change in performance on a battery
neuropsychometric tests as outcome measure. Study will recruit patients based on their
preexisting statin regimen.
The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use
is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early
mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against
eCD.